-
Product Insights
Likelihood of Approval Analysis for Low-Grade Glioma
Overview How likely is it that the drugs in Low-Grade Glioma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Low-Grade Glioma Overview Low-grade gliomas are benign grade 1 and grade 2...
-
Case Studies
NewEco Tourism Case Study – Analysing Key Trends, Destinations, Opportunities and Challenges
Eco Tourism Report Overview Eco tourism focuses on planning trips to beautiful destinations while minimizing environmental impact and promoting local economies. Eco Tourism is a sustainable travel experience that promotes responsible use of natural resources, reducing pollution and waste. It encourages responsible energy consumption, renewable energy sources, and single-use plastics. The eco-tourism case study provides an overview of the eco tourism industry. The report determines the key market drivers, and emerging trends, as well as highlights the opportunities and major...
-
Product Insights
Likelihood of Approval Analysis for Asthma
Overview How likely is it that the drugs in Asthma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Asthma Overview Asthma is a long-term inflammatory disease of the airways of the...
-
Sector Analysis
NewInsurance Broker Market Size and Analysis by Region, Regulatory Trends, Competitive Landscape and Forecast to 2028
Insurance Broker Market Report Overview Brokers’ written premiums are estimated to be $1,341.2 billion in 2024. The growing complexity of risks and disruptions and the launch of data-driven products and services leveraging innovative technologies will promote the brokers’ written premium growth at a CAGR of more than 7% during 2024-2028. Currently, brokers actively incorporate environmental, social, and governance (ESG) principles into their businesses to cater to clients. Brokers such as Marsh, WTW, Truist Insurance Holdings, and Gallagher have committed to...
-
Thematic Analysis
NewConstruction M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Construction Sector
-
Product Insights
Likelihood of Approval Analysis for Rhino-Conjunctivitis
Overview How likely is it that the drugs in Rhino-Conjunctivitis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhino-Conjunctivitis Overview Rhinitis is characterized by one or several of the following symptoms:...
-
Product Insights
Likelihood of Approval Analysis for Pulmonary Fibrosis
Overview How likely is it that the drugs in Pulmonary Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Fibrosis Overview Pulmonary fibrosis is a lung disease that causes lung...
-
Product Insights
Likelihood of Approval Analysis for Arteritis
Overview How likely is it that the drugs in Arteritis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arteritis Overview Arteritis refers to the inflammation of arteries, which are the blood...
-
Product Insights
Likelihood of Approval Analysis for Anxiety Disorders
Overview How likely is it that the drugs in Anxiety Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anxiety Disorders Overview Anxiety disorders are a group of mental health conditions...
-
Product Insights
Likelihood of Approval Analysis for Macular Degeneration
Overview How likely is it that the drugs in Macular Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macular Degeneration Overview Macular degeneration is primarily an age-related retinal condition. There...